AIT Therapeutics Reports Second Quarter 2017 Financial Results

Published: Aug 11, 2017

REHOVOT, Israel and NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced financial results for the three- and six-months ended June 30, 2017.

Operational and Financial Highlights include:

Enrolled the first patient in the Nitric Oxide for NTM abscessus (NO-NTM abscessus) Phase 2 clinical trial in patients with Mycobacterium Abscessus Complex (MABSC), the most severe form of nontuberculous mycobacteria (NTM), with data expected in the fourth quarter of 2017.

Back to news